Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2008

View Archived Issues

Inositol hexaphosphate reduces cellular growth of bladder cancer in vitro

Selective inhibitor of human tryptase shows benefit in models of asthma and rhinitis

LASSBio-596 active in mouse model of silicosis

CCR4 antagonist K-327, potentially useful in allergic airways inflammation

Novartis launches Tasigna in the U.K. for Philadelphia chromosome-positive CML

ImmuneRegen announces preliminary results from dermatological testing of Homspera

ImmuPharma reports preclinical data on nucleolin antagonist peptide IPP-204106

Palatin initiates dosing in phase IIa clinical study of PL-3994 for hypertension

SWOG initiates enrollment in phase I clinical trial of ImClone Systems' IMC-A12

KAI Pharmaceuticals initiates enrollment in phase I clinical study of KAI-1678

Ceragenix announces results from comparison study of EpiCeram cream in pediatric AD

Alizyme commences phase II Colal-Pred study in the U.S.

BioAlliance acquires European rights to ondansetron oral spray

Bone Medical receives FDA confirmation for Capsitonin clinical trial strategy

Denosumab study meets primary and secondary bone mineral density endpoints

Sangart completes enrollment in second phase III Hemospan study

Transgene presents promising phase I preliminary results of its HCV vaccine

VGX files two separate INDs for novel cervical cancer and avian flu DNA vaccines

FDA approves Entereg for management of postoperative ileus

Recent Wyeth and Takeda patents disclose novel antipsychotic and antidepressant agents

Recent Fujifilm and AstraZeneca patents describe new diagnostic agents

New antibacterial agents reported in recent Novartis patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...